WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here

Search

Track Your Article

Abstract

STUDY TO EVALUATE THE EFFICACY OF KALA VASTI [RASNADASHMOOLAKAM AND SAINDHVADYA TAILA BRHAT] IN AMAVATA (RHEUMATOID ARTHRITIS)

Dr. Alka Narnolia* and Prof. (Dr.) N. R. Singh

ABSTRACT

Introduction: Amavata was firstly described by Madhavakara in 700AD and mentioned that Ama and Vata plays a vital role in the pathogenesis of this disease. Ama is caused due to derangement of Agni especially Jatharagni. It is initiated by the consumption of Virudha Ahara (incompatible food) in the pre-existence of Mandagni. In it vitiated Vayu forcefully circulates the Ama all over the body through Dhamnies (circulatory channels) which take shelter in the Sleshma sthana [Amashyas, Sandhi etc.] producing symptoms of Amavata. Rheumatoid Arthritis is a chronic inflammatory disease of unknown aetiology marked by a symmetric, peripheral polyarthritis, often result in joint damage and physical disability. Serum antibodies to cyclic citrullinated peptide (Anti-CCPs) are routinely used along with Rheumatoid factor as a bio marker of diagnostic and prognostic significance. About 0.8% (0.3% to 2.1%) of the population worldwide is affected by this disease. In India the prevalence of this disease is 0.5% to 0.75%. Mostly the middle age group persons are affected. Aim and Objective: Aim- To evaluate the efficacy of Kala Vasti (Rasnadashmoolakam and Saindhvadya Taila Brhat) in the management of Amavata (Rheumatoid Arthritis). Objective- Reduction of Subjective parameters, Objective parameters and Biochemical parameters of Amavata (Rheumatoid Arthritis). Material and Methods: A total of 48 patients were registered according to inclusion and exclusion criteria and randomly (by chit lottery method) divided into two groups from Kayachikitsa OPD / IPD of CBPACS, New Delhi and 40 patients were completed the trial. Group-A will be administered Kala Vasti (Niruha Vasti with Rasnadashmoolakam and Anuvasana with Saidhvadya Taila Brhat). Group-B will be administered (Niruha Vasti- Vaitarana Vasti and Anuvasana with Saidhvadya Taila Brhat) as per Kala Vasti schedule. Observation and Result: In Group A, showed highly significant results p<0.001 in Jwara, Sandhiruja, Sandhisotha, Ritchie Articular index (RAI), DAS 28 criteria, VAS (Visual Analogue Scale), Walking time, ESR, CRP and in Stabdhta, Gaurava, grip strength, RA factor was significant result p<0.05. In Group B, showed highly significant result p<0.001 in Stabdhta, Gaurava, Sandhiruja, Sandhisotha, RAI (Ritchie Articular index), DAS 28 criteria, grip strength, VAS (Visual Analogue Scale), ESR, RA factor and in Jwara, Walking Time, CRP was significant result p<0.05. There were no adverse effects or complications found after completing the therapy. Conclusion: Administration of Kala Vasti- Anuvasana Vasti of Saindhvadya Taila Brhat and Niruha Vasti of Rasnadashmoolakam and Vaitarana Vasti is a safe and effective medication for Amavata.

Keywords: Ama, Vata, Amavata, Rheumatoid arthritis, Kala Vasti, Rasnadashmoolakam.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More